Search results for "vegf"

showing 10 items of 148 documents

Hyaluronic acid based nanohydrogels fabricated by microfluidics for the potential targeted release of Imatinib: Characterization and preliminary eval…

2019

Abstract Microfluidics is emerging as an innovative technique for the “on chip” fabrication of nanoparticles for drug delivery applications. Here, by using an amphiphilic derivative of hyaluronic acid as a starting macromolecule, nanohydrogels loaded with Imatinib were produced by the microfluidic procedure in order to develop an innovative therapeutic tool for the treatment of retinal neovascularization. Both cyRGDC functionalized and non-functionalized nanohydrogels were designed and fabricated by using the same technique. The targeting efficiency of the obtained nanosystems was studied in vitro on human retinal pigment epithelial cells (HRPEpiC) and human umbilical vein endothelial cells…

Cell SurvivalDrug CompoundingHyaluronic acidMicrofluidicsMicrofluidicsPharmaceutical ScienceAngiogenesis Inhibitors02 engineering and technologyRetinal Pigment Epithelium030226 pharmacology & pharmacyTHERAPYUmbilical veinANGIOGENESISNeovascularization03 medical and health scienceschemistry.chemical_compoundNanoparticle0302 clinical medicineLab-On-A-Chip DevicesAmphiphileHyaluronic acidmedicineHuman Umbilical Vein Endothelial CellsHumansPEPTIDEDRUG-DELIVERYNeovascularizationDrug CarriersChemistryImatinibHydrogels021001 nanoscience & nanotechnologyRANIBIZUMABVEGFIn vitroChoroidal NeovascularizationNanostructuresINTEGRINSMicrofluidicDrug deliveryImatinibImatinib MesylateFeasibility StudiesNanoparticlesmedicine.symptomTargeted delivery0210 nano-technologyBiomedical engineeringmedicine.drug
researchProduct

Efficacy and safety study of an eyelid gel after repeated nocturnal application in healthy contact lens users and non-users

2020

Purpose: To evaluate skin biocompatibility of a nighttime hydrating eyelid gel and possible ocular surface effects in contact lens users (CLU) and non-contact lens users (NCLU). The formulation is registered as a medical device as Tridocosahexaenoine-AOX® (TDHA-AOX) (a concentrated DHA triglyceride), containing also hyaluronic acid (HA). Methods: A prospective, randomized, masked clinical trial was performed with 62 participants of both sexes, aged 20–70 years, split into: (1) CLU (n = 30) and (2) NCLU (n = 32). All participants were instructed to apply a single dose of the moisturizing gel (containing TDHA-AOX and HA) nightly to the upper and inner eyelids of their right eye (RE) only, and…

DHA docosahexaenoic acidNon usersFBUT fluorescein break-up timeALA alpha linolenic acidTDAH-AOX tridocosahexaenoin-antioxidantNCLU non contact lens users0302 clinical medicineLC PUFAs long chain polyunsaturated fatty acidsMedicineCL contact lensesOS ocular surfaceHA hyaluronic acidOSDI ocular surface disease indexDE dry eyeCLU contact lens usersCLDEQ contact lens dry eye questionnaireVEGF vascular endothelial growth factorDocosahexaenoic acidBMC biomicroscopymedicine.anatomical_structureMedicamentosCytokinesOftalmologíaOriginal ArticleBCVA best corrected visual acuitymedicine.medical_specialtyOcular surface dysfunctionCorneal stainingContact LensesHyaluronic acidRE right eyeDEs dry eye syndrome03 medical and health sciencesOphthalmologyHumansAdverse effectbusiness.industryEyelidsEPA eicosapentaenoic acidAnatomía ocularIOP intraocular pressureeye diseasesClinical trialContact lensMOISTURIZING GEL030221 ophthalmology & optometryTearsLE left eyeEyelidsense organsbusiness030217 neurology & neurosurgeryOptometry
researchProduct

Microenvironmental adaptation of experimental tumours to chronic vs acute hypoxia

2004

This study investigated long-term microenvironmental responses (oxygenation, perfusion, metabolic status, proliferation, vascular endothelial growth factor (VEGF) expression and vascularisation) to chronic hypoxia in experimental tumours. Experiments were performed using s.c.-implanted DS-sarcomas in rats. In order to induce more pronounced tumour hypoxia, one group of animals was housed in a hypoxic atmosphere (8% O(2)) for the whole period of tumour growth (chronic hypoxia). A second group was acutely exposed to inspiratory hypoxia for only 20 min prior to the measurements (acute hypoxia), whereas animals housed under normal atmospheric conditions served as controls. Acute hypoxia reduced…

DNA ReplicationMaleCancer ResearchPathologymedicine.medical_specialtyBiologyperfusionRats Sprague-Dawleychemistry.chemical_compoundOxygen ConsumptionVascularityIn vivomedicineAnimalsExperimental TherapeuticshypoxiaCell growthDNA NeoplasmNeoplasms ExperimentalOxygenationHypoxia (medical)VEGFCell HypoxiaRatsVascular endothelial growth factorDisease Models AnimalKineticscell proliferationBlood pressureOncologychemistryvascularityAcute DiseaseChronic Diseaseoxygenationmedicine.symptomPerfusionCell DivisionBritish Journal of Cancer
researchProduct

MECHANISM OF DIABETIC NEPHROPATHY: ROLE OF VEGF-A

Diabetes; DIABETIC NEPHROPATHY; VEGFDIABETIC NEPHROPATHYDiabeteVEGF
researchProduct

Diabētiskās makulopātijas izmaiņas pacientiem pēc anti-VEGF intravitreālām injekcijām

2015

Diabētiskās retinopātijas (DR) biežākais redzes pasliktināšanās iemesls ir makulas tūska. Kopš 2006. gada diabētisku makulopātiju (DM) ārstē ar anti – vaskulārā endotēlija augšanas faktora inhibotoru (anti-VEGF) preparātiem un viens no tiem ir (Bevacizumab) preparāts Avastin. Anti-VEGF terapija uzskatāma par mazāk traumatisku terapiju, tāpēc anti-VEGF terapija tiek pētīta sīkāk. Avastin preparāts tiek plaši pielietots vairākās klīnikās visā pasaulē, jo ir salīdzinoši lētāks un konkurētspējīgāks preparāts ārstēšanas efekta ziņā. Mans darba mērķis ir izvērtēt ārstēšanas efektivitāti, apkopojot un analizējot datus par makulas tūskas un redzes asuma izmaiņām, pēc intravitreālām Avastin injekcij…

Diabētiska retinopātijaAnti-VEGFDiabētiska makulopātijaMedicīna
researchProduct

ESPRESSIONE DI VEGF, HSP90 E Bip/GRP78 E RICORRENZA DI CARCINOMA EPATOCELLULARE DOPO TRAPIANTO DI FEGATO

Background and aims Liver transplantation (LT) for hepatocellular carcinoma (HCC) is a satisfactory therapeutic choice in patients with “early HCC” selected according to Milan criteria. However, the risk of HCC recurrence after LT is about 7-10% at five years and markers which can predict recurrence are still lacking. We investigated in HCC samples and LC surrounding tissues the significance of VEGF, HSP90, and Bip/GRP78 expression in patients with HCC who underwent LT in a western transplantation center and their possible role as markers of recurrence. Background and aims Liver transplantation (LT) for hepatocellular carcinoma (HCC) is a satisfactory therapeutic choice in patients with “ea…

EPATOCARCINOMA E VEGF HSP90 Bip/grp78Settore MED/09 - Medicina Interna
researchProduct

VEGFR-2, HSP90 and GRP78/BiP expression and HCC recurrence after Liver Transplantation

2018

Introduction Liver transplantation (LT) for hepatocellular carcinoma (HCC) is a satisfactory therapeutic choice in patients with “early HCC” selected according to Milan criteria. However, the risk of HCC recurrence after LT is about 7-20% at five years and molecular markers which can predict recurrence are still lacking. We investigated in HCC samples and LC surrounding tissues the significance of VEGFR-2, HSP90, and GRP78/BiP expression in patients with HCC who underwent LT in a western transplantation center and their possible role as molecular markers of recurrence. Methods 42 patients (35 M, 7 F) with early HCC who underwent LT between 2012 and 2013 were enrolled. The tumor recurrence r…

GRP78/BiPVEGFR-2Liver transplantationHepatocellular carcinomaHSP90Microvascular invasion
researchProduct

Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators

2022

Background & aims: Activation of Kupffer cells and recruitment of monocytes are key events in fibrogenesis. These cells release soluble mediators which induce the activation of hepatic stellate cells (HSCs), the main fibrogenic cell type within the liver. Mer tyrosine kinase (MerTK) signaling regulates multiple processes in macrophages and has been implicated in the pathogenesis of non-alcoholic steatohepatitis-related fibrosis. In this study, we explored if MerTK activation in macrophages influences the profibrogenic phenotype of HSCs. Methods: Macrophages were derived from THP-1 cells or differentiated from peripheral blood monocytes towards MerTK+/CD206+/CD163+/CD209- macrophages. Th…

HepatologyCM conditioned medium ECM extracellular matrix Gas-6 Gas-6 growth arrest-specific gene 6 HSC(s) hepatic stellate cells KC(s) Kupffer cell(s) M-CSF macrophage colony-stimulating factor M2c-like macrophages MerTK Myeloid-epithelial-reproductive tyrosine kinase NAFLD non-alcoholic fatty liver disease NASH NASH non-alcoholic steatohepatitis PMA phorbol 12-myristate 13-acetate TGFβ1 transforming growth factor-β1 THP-1 TIMP1 tissue inhibitor of metalloproteinase 1 VEGF-A vascular endothelial growth factor-A liver fibrosis siRNA small-interfering RNAGas-6; liver fibrosis; M2c-like macrophages; NASH; THP-1GastroenterologyInternal MedicineImmunology and AllergyJHEP Reports
researchProduct

In Vivo Nuclear Imaging of Hypoxia as Predictive Biomarkers and follow up the Response to Anti-VEGF Therapies in Idiopathic Pulmonary Fibrosis

2022

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal disease of unknown origin. In France, it is one of the most common interstitial pathologies (IP) and affects 4,400 new people each year. IPF is characterized by dysregulated healing mechanisms that lead to the accumulation of large amounts of collagen in the lung tissue and cause disorganization of the alveolar architecture. It results in progressive deterioration of the respiratory function, leading in a few years to chronic respiratory failure and then to death. Idiopathic pulmonary fibrosis has a lower survival rate than many cancers with a median survival of 2 to 5 years from diagnosis. This pathology whose main ris…

HypoxieDiagnostic toolIpfFpiOutil diagnostiqueAnti-VEGFImagerie nucléaireHypoxiaNuclear imaging[SDV.BC] Life Sciences [q-bio]/Cellular Biology
researchProduct

Cyclooxygenase- 2, Tumor Necrosis Factor-α, Vascular Endothelial Growth Factor-A and IL-6 genes SNPs and IL-6 serum levels in liver cirrhosis and hep…

2011

IL-6liver cirrhosiCOX-2HCCVEGF-ApolymorphismTNF-alphaCYCLOOXYGENASE-2 TUMOR NECROSIS FACTOR-a VASCULAR ENDOTHELIAL GROWTH FACTOR-A IL-6 GENES SNPS LIVER CIRRHOSIS HEPATOCELLULAR CARCINOMA
researchProduct